LONDON, Nov. 26 /CNW/ - Daval International Limited, a UK private
company, announces MHRA and IRB (Ethics Committee) approval of a London based
Phase IIB trial of AIMSPRO(R), its hyperimmune caprine serum derivative.
This double-blind placebo-controlled cross-over study will seek to detect
a beneficial effect on bladder function in patients with Secondary Progressive
Multiple Sclerosis, following open-label observations over several years in a
number of informed consent, "compassionate basis" patients.
AIMSPRO has an "export only" listing on the Australian Registry of
Therapeutic Goods and a TGA Orphan Status Designation for the treatment of
Krabbe's disease. An IND application is being lodged for a further MS trial in
the United States.
AIMSPRO is a frozen medication, given as a 1ml sub-cutaneous injection
every 4 days. It is believed to have a pronounced and sustained
anti-inflammatory action with an associated, novel effect of lowering sodium
channel triggering voltages in nerve fibres. MHRA applications for two further
clinical trials are to be lodged within the next 3 months.
Daval International Ltd. has recently been accepted as a member of the
Association of the British Pharmaceutical Industry. "APBI"
Daval International Limited
Daval International Limited is a privately owned British pharmaceutical
company, which, since 2001, has been developing an immunologically active
human and veterinary medication derived from goat serum. Some 20,000 doses of
Aimspro have been administered, mainly to human subjects with multiple
sclerosis, with an excellent safety and tolerance profile.
For further information:
For further information: email@example.com, Dr.Bryan Youl,
+44(0)779-352-6096; Brian Quick, +44(0)776-482-8114